Special Issue

Oral Cancer: From Pathophysiology to Novel Therapeutic Approach

Message from the Guest Editor

Oral cancer continues to be a significant global health concern, with rising incidence rates and persistent challenges in early detection, treatment resistance, and disease recurrence. This Special Issue comprehensively explores the molecular mechanisms, cellular interactions, and genetic predispositions underlying oral cancer pathophysiology. Additionally, it highlights emerging diagnostic strategies and novel therapeutic approaches that have the potential to improve patient outcomes. Key topics covered in this issue include molecular and cellular mechanisms, biomarkers for early detection and prognosis, targeted and immunotherapeutic strategies, and precision medicine and personalized therapies. By compiling innovative research and expert reviews, this Special Issue bridges the gap between fundamental research and clinical application, promoting the development of more effective strategies for the prevention, diagnosis, and treatment of oral cancer. Researchers, clinicians, and healthcare professionals are encouraged to contribute their findings and foster interdisciplinary collaborations to combat this devastating disease.

Guest Editor

Dr. Chan-Yen Kuo

Institute of Oral Medicine and Materials, College of Medicine, Tzu Chi University, Hualien 970, Taiwan

Deadline for manuscript submissions

31 March 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/233003

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).